Browsing Tag
Candida auris
1 post
SCY-247 intravenous trial signals strategic shift in SCYNEXIS, Inc.’s antifungal pipeline
SCYNEXIS, Inc. advances IV SCY-247 into Phase 1. Discover what this signals for antifungal resistance and hospital markets.